- Home
- INO vs ELUT Comparison
INO vs ELUT Comparison
Compare INO & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INO
- ELUT
- Stock Information
- Founded
- INO 1979
- ELUT 2015
- Country
- INO United States
- ELUT United States
- Employees
- INO N/A
- ELUT N/A
- Industry
- INO Medical/Dental Instruments
- ELUT Medical Specialities
- Sector
- INO Health Care
- ELUT Health Care
- Exchange
- INO Nasdaq
- ELUT Nasdaq
- Market Cap
- INO 69.3M
- ELUT 79.7M
- IPO Year
- INO 1998
- ELUT 2020
- Fundamental
- Price
- INO $2.38
- ELUT $1.28
- Analyst Decision
- INO Buy
- ELUT Strong Buy
- Analyst Count
- INO 5
- ELUT 2
- Target Price
- INO $8.80
- ELUT $7.00
- AVG Volume (30 Days)
- INO 2.7M
- ELUT 181.4K
- Earning Date
- INO 11-13-2025
- ELUT 11-13-2025
- Dividend Yield
- INO N/A
- ELUT N/A
- EPS Growth
- INO N/A
- ELUT N/A
- EPS
- INO N/A
- ELUT N/A
- Revenue
- INO $182,337.00
- ELUT $23,683,000.00
- Revenue This Year
- INO N/A
- ELUT $19.68
- Revenue Next Year
- INO $15,775.73
- ELUT $70.28
- P/E Ratio
- INO N/A
- ELUT N/A
- Revenue Growth
- INO N/A
- ELUT N/A
- 52 Week Low
- INO $1.30
- ELUT $1.28
- 52 Week High
- INO $7.00
- ELUT $5.12
- Technical
- Relative Strength Index (RSI)
- INO 55.04
- ELUT 26.11
- Support Level
- INO $2.33
- ELUT $2.18
- Resistance Level
- INO $2.98
- ELUT $2.38
- Average True Range (ATR)
- INO 0.22
- ELUT 0.20
- MACD
- INO -0.01
- ELUT -0.11
- Stochastic Oscillator
- INO 43.93
- ELUT 0.00
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
About ELUT Elutia Inc.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.